Article Text

Download PDFPDF

P166 Possible new role for HCQ in preventing depression in jSLE?
  1. Sara Ganhão1,
  2. Beatriz Silva2,
  3. Francisca Aguiar1,
  4. Mariana Rodrigues1,
  5. Iva Brito1,2 and
  6. Margarida Figueiredo-Braga2,3
  1. 1Young Adult and Pediatric Rheumatology Unit, Centro Hospitalar e Universitário do Hospital de São João, Porto
  2. 2Faculty of Medicine, University of Porto, Porto
  3. 3Dept. of Clinical Neurosciences and Mental Health, Porto, Portugal


Background Hydroxychloroquine (HCQ) is a key immunomodulatory treatment in systemic lupus erythematosus (SLE) with pleiotropic effects. Beyond anti-thrombotic, anti-atherosclerotic and anti-diabetic effects, anti-microbial and anti-cancer are possible roles. Neuropsychiatric symptoms, mostly headaches, depression, anxiety and cognitive impairment, affect nearly half of patients. Several pathways have been identified: antibody-mediated/cytokine-induced neurotoxicity, vasculopathy and loss of neuroplasticity. Thus, we hypothesized if there is a role for HCQ in preventing depression in jSLE.

Methods A cross-sectional sample of juvenile-onset SLE (jSLE) patients, currently aged ≥ 16 years, completed a psychosocial assessment including the SF-36, HADS, SHS, BriefCope and MMSE questionnaires, between October 2018- May 2019. Local Ethics Committee approved the study. All patients fulfilled both 2012 and 2019 EULAR/ACR classification criteria for SLE. Juvenile-onset was defined as age at diagnosis <18 years. Demographics and clinical characteristics were collected. Statistical analysis was performed with SPSS®.

Results 30 jSLE patients were included (90%female) in the study, with median age of 21 years, being the youngest 16 and the oldest 35, with mean (SD) age of diagnosis of 15.8 ± 2.1. Mean values (SD) of psychosocial assessment were: SHS 5.2 (1.02); MMSE of 27.7 (1.8); Physical health SF-36 of 66.8 (9.9) and Mental health SF-36 of 68.9 (17.5). 23.3% jSLE showed mild cognitive impairment, 63.3% anxiety and 13.3% depression. From the 27 jSLE treated with HCQ, those had better results in the SHS (p=0.030) and scored lower in scores in the Hospital Anxiety and Depression scale (p=0.023). Interestingly, this also occurs for emotion focused coping, with significantly better results in jSLE taking HCQ (p=0.001).

Conclusions Young adults with SLE are at risk for depression and HCQ may have a role in preventing it. Longitudinal studies will permit to confirm present results and clarify the role of coping strategies in the occurrence of depression in jSLE.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.